Rubius Therapeutics (RUBY) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Rubius Therapeutics (NASDAQ:RUBY) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. “

Shares of RUBY stock opened at $14.46 on Wednesday. Rubius Therapeutics has a 52 week low of $12.70 and a 52 week high of $33.01. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64.

Rubius Therapeutics (NASDAQ:RUBY) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04). On average, equities analysts forecast that Rubius Therapeutics will post -1.8 EPS for the current fiscal year.

In other news, President Torben Straight Nissen sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $20.00, for a total value of $42,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Langer sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $17.57, for a total transaction of $131,775.00. The disclosure for this sale can be found here. Insiders sold a total of 70,196 shares of company stock valued at $1,186,015 in the last quarter. Corporate insiders own 58.40% of the company’s stock.

Several large investors have recently modified their holdings of RUBY. Legal & General Group Plc acquired a new position in shares of Rubius Therapeutics in the 3rd quarter valued at approximately $44,000. New York State Common Retirement Fund acquired a new position in shares of Rubius Therapeutics in the 4th quarter valued at approximately $116,000. Metropolitan Life Insurance Co. NY raised its position in shares of Rubius Therapeutics by 320.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock valued at $116,000 after buying an additional 5,481 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Rubius Therapeutics in the 1st quarter valued at approximately $117,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Rubius Therapeutics by 19,092.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,485 shares of the company’s stock valued at $135,000 after purchasing an additional 7,446 shares during the last quarter. Institutional investors own 93.75% of the company’s stock.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Recommended Story: What is the quiet period?

Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.